A New Clock is Running for Multiple Myeloma: Circadian Clock Protein-Period 3 (PER-3) Polymorphism
, , , and | May 02, 2023
About this article
Article Category: ORIGINAL ARTICLE
Published Online: May 02, 2023
Page range: 37 - 43
DOI: https://doi.org/10.2478/bjmg-2022-0026
Keywords
© 2022 Pehlivan S. et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1.
Comparison of PFS and OS with prognostic factors of patients with MM
| PFS |
Log Rank p-value | os |
Log Rank p | |||
|---|---|---|---|---|---|---|
| n | 52.7 | 77 |
||||
| 73/77 | 89.3 /39.2 | 0.080 | 66 |
0.690 | ||
| 130/20 | 54.3 / 40.4 | 0.230 | 56 |
0.058 | ||
| 38/84 | 28.5 / 54.3 | 0.257 | 87.1 / 99.1 | 0.229 | ||
| 91/31 | 40.4 / 65.0 | 0.277 | 55 |
0.301 | ||
| 39 | 69.3 | 99.1 | ||||
| 34 | 40.4 | 70 |
||||
| 50 | 52.7 | 0.764 | 88.2 | |||
| 109/12 | 47.1 / 28.5 | 0.959 | 53 |
0.301 | ||
| 116/7 | 52.7 / 17 | 0.086 | 53 |
|||
| 51/71 | 54.3 / 52.7 | 0.686 | 85 |
0.057 | ||
| 4R/4R | 70 | 40.4 | 74 |
|||
| 4R/5R | 64 | 69.3 | 57 |
|||
| 5R/5R | 16 | 86 |
100 |
0.349 | ||
| 4R/4R | 70 | 40.4 | 63 |
|||
| 4R/5R -5R/5R | 80 | 89.6 | 99.1 | 0.738 |
Comparison of frequencies of PER-3 gene variants between patients with MM and healthy controls
| PER3 | Genotype | Multiple Myeloma | Healthy Controls | OR Exp(B) | 95% CI | p |
|---|---|---|---|---|---|---|
| n= |
n=100 (%) | |||||
| 4R/4R | 70 (46.7) | 42 (42) | 0.657 |
0.285-1.517 |
0.325 |
|
| 4R/5R | 64 (43.3) | 44 (44) | 0.745 |
0.320-1.734 |
0.494 |
|
| 5R/5R | 16 (10.7) | 14 (14) | 1.363 |
0.633-2.935 |
0.434 |
|
| 4R | 204 (67.5) | 128 (64) | ||||
| 5R | 98 (32.5) | 72 (36) | 1.159 |
0.796-1.689 |
0.443 |
Clinical features and treatment regimens of MM patients
| Multiple Myeloma | Control | Control | p | |||
|---|---|---|---|---|---|---|
| median | n |
median | n |
|||
| Age | 56 (32-70) | 53 (28-68) | 0.140 |
|||
| Gender | Female/Male | 77/73 (51.3/48.7) | 55/45 (55/45) | 0.367 |
||
| MM Subtypes | κ/λ | 83/39 (68/32) | ||||
| G/A | 79/18 (65/15) | |||||
| Light chain | 25 (20) | |||||
| Stage (Durie-Salmon) | II/III | 38/84 (25/75) | ||||
| A/B | 91/31 (79/21) | |||||
| IPI | I | 39 (32) | ||||
| II/III | 34/50 (28/40) | |||||
| ECOG | >1 | 12 (10) | ||||
| Hemoglobin | gr/dL | 10.4 (6.2-15) | ||||
| Leukocyte | mm3 | 7200 (2760-18500) | ||||
| Platelet | 103μL | 172 (69-406) | ||||
| C-reactive protein | mg/dL | 8 (2.1-352) | ||||
| LDH | IU/L | 212 (93-1037) | ||||
| B2-microglobulin | mg/L | 4.9 (1.5-48) | ||||
| Albumin | gr/L | 3.5 (1.6-5.1) | ||||
| Treatment | VCD, ASCT, LD | |||||
| OS (10-years, %) | (79) | |||||
| PFS (10-years, %) | (47) – 52.7 months | |||||
| Relapse | 63 (42) | |||||
| Mortality | 23 (15.3) | |||||
| Follow-up duration, months, (range) | 36.1 (4.1-155.2) |
Multivariate analysis of 150 MM patients (Cox proportional hazard model backward)
| PFS | ||||
|---|---|---|---|---|
| Exp (B) | %95 CI | p | ||
| 4R/4R | 0.488 | 0.284-0.837 | ||
| ≥480 | 0.441 | 0.170-1.141 | 0.091 | |
| Female/Male | 0.604 | 0.357-1.022 | 0.060 | |